The US Food and Drug Administration (FDA) has agreed once again to review a kidney cancer drug for approval, and noteworthy results from a phase 3 trial of a different drug for kidney cancer may yield further exploration.
Aveo Pharmaceuticals (Cambridge, MA) filed a New Drug Application (NDA) with the FDA. Aveo is seeking approval for tivozanib (brand name Fotivda), a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) to treat relapsed or refractory renal cell carcinoma (RCC). The drug was approved for the European market in 2017.
Aveo failed to obtain US approval in 2013 and again in